Скачать или смотреть “Oral Proteins & Peptides Market: The Next Big Leap in Drug Delivery”

Market Definition
Oral proteins and peptides are biologically active macromolecules made of amino acids, used for therapeutic and nutritional purposes, with applications in treating conditions like diabetes, cancer, and hormonal imbalances. Advances in formulation and drug delivery improve their stability and bioavailability.

The market covers the development, production, and commercialization of these molecules, including therapeutic proteins (e.g., insulin, growth factors) and nutritional supplements.

Key applications include diabetes, cancer, hormonal imbalances, and autoimmune diseases, with market growth driven by advancements in drug delivery and rising demand for protein-based therapies.

Oral Proteins and Peptides Market Overview
The global oral proteins and peptides market size was valued at USD 6,350.0 million in 2023 and is projected to grow from USD 7,462.0 million in 2024 to USD 26,936.2 million by 2031, exhibiting a CAGR of 20.13% during the forecast period.

This market is registering rapid expansion, fueled by advancements in biotechnology, increasing adoption of biologics, and the increasing prevalence of chronic diseases such as diabetes, cancer, and autoimmune disorders. The shift toward patient-friendly and non-invasive drug administration has significantly increased interest in oral formulations over injectable alternatives.

Pharmaceutical companies are investing heavily in research and development to enhance the stability, absorption, and efficacy of these macromolecules, leading to the introduction of innovative drug delivery technologies such as nanoparticle carriers, permeation enhancers, and enzyme inhibitors.

Major companies operating in the oral proteins and peptides industry are Novo Nordisk A/S, AbbVie Inc., Pfizer Inc., Biocon Limited, Groupe Sanofi, Oramed Pharmaceuticals Inc, Johnson & Johnson Services, Inc., EnteraBio Ltd., Chiesi Farmaceutici S.p.A., Proxima Concepts, Tarsa Therapeutics, Inc., and Synergy Pharma.

Moreover, the expanding geriatric population, which requires long-term and convenient treatment options, is further driving demand. Collaborations between biotech firms and pharmaceutical companies are also fostering advancements in drug formulations, ensuring wider availability of effective oral therapies.
  For More Insights: Discover in-depth analysis, trends, and key forecasts in the official report by Kings Research:-

https://www.kingsresearch.com/oral-pr...